receptor sites, by mimicking or blocking the action of a neurohormone. In recent years many drugs have been shown to influenee the nervous system indirectly by modifying the amount of a free,neurohormone at receptor sites. For example, reserpine changes the quantity of a free monoamine at receptors by impairing its sites of storage. Drugs also alter the quantity of a free monoamine by inhibiting its synthesis, metabolism, or physiolooic release." It seems logical to consider all these sites of drug action as parts of an organized molecular unit responsible for the formation, storage, inactivation, and physiologic release of a neuiroliormone.
Since these molecular units transform one kind of energy into another, the term neurochemical transducer has been coined to describe them. Thuis, electrical impulses arriving at the nerve endinz act on the transduicer and are translated into a quantity of free hormone. The free amine in tutrn acts on a target organ to produce chemical or mechanical enerqy, or on another neuron to produice additional electrical impulses (flg. 1). The neuroehemical transducer contains a store of norepinephrine, epinephrine, dopamine, serotonin, or acetyleholine and is present in each of the billions of synapses and nerve endings in the body. They are really the primary units of behavior, since the organism responds to environmental change only because these units can regulate precisely the quantity of free neurohormone at nerve endings.
The functional organization of these units is one of the fundamental problems in biolFrom the Laboratory of Chemical Pharmacology, National Heart Institute, National Institutes of Healtb, Bethesda, Maryland. ogy. However, the efforts by the biochemists, physiologists, and pharmacologists to disclose the nature of these molecular units have been hampered by failure to study them as complete entities rather than considering them as separate processes of synthesis, storage, and metabolism. Homogenization destroys the structural integrity of these organized units and it is necessary to study them in the living animal or in the intact organ tissues.
The availability of tritium-labeled norepinephrine (H3NE) of high activity has permitted observations of the properties of sympathetic nerve endings in vivo from which a structure of the neurochemical transducer for the cateeholamine can be formulated. Similar studies with labeled serotonin have been carried out but will not be reported in this paper. Although the concept is still schematized and fragmentary and, at best, only a tentative working hypothesis, it is proving a valuable framework on which to prediet the action of drugs.
Concept of Organized Molecular Units at Sympathetic Nerve Endings I shall describe briefly our speculations about the nature of the biophysical units at sympathetic nerve endings as well as the data on which these speculations are built. Since norepinephrine does not freely diffuse onto receptor sites and is relatively stable in tissues, it must be sequestered by an intracellular boundary, presumably lipoidal in nature ( fig. 2 ). Since the concentration of norepinephrine at nerve endings is much greater than in extracellular fluid, something more than a lipoidal membrane is needed to explain its storage.
The nature of the storage mechanism has been explored by kinetic studies of the uptake of labeled monoamines by various tissues. results indicate that active transport is the key process which maintains the amines in various tissues.
For example, studies from this laboratory have shown that the high level of serotonin in blood platelets is maintained by a specialized transport system2 which is inhibited by reserpine, ouabain, and N-ethylmaleimide. 3 4 When tracer amounts of radioactive serotonin are added to a platelet suspension, after a steady-state with unlabeled amine has been established, the uptake of labeled amine is still rapid although the net uptake of total amine is zero, indicating that the concentrating mechanism is acting continuously by a "pump and leak" mechanism. 4 The storage of norepinephrine in nervous tissue is a more complex process since sites of storage, formation, and inactivation are all together, and amine-containing granules are present. Kinetic studies by Titus et al. from this laboratory have shown that brain and heart slices take up H3NE against a concentrationi gradient by a process that is blocked by reserpine and poisoned by ouabain. 5 The kinetics of uptake indicate that active transport is an integral part of the mechanism holding endogenous norepinephrine in storage and that this mechanism can also be regarded as a pump which resists the free outward diffusion of the amine formed inside the storage compartment. Included in these experiments was one showing that the preloading of brain slices with unlabeled norepinephrine does not slow the uptake of H3NE, inidicating iil aniother way that the uptake systein is contitiually acting. These investigators pointed out that isotopic equilibrium between labeled norepinephrine in medium and in slices is not reached by the time that the H3NE level within the slices has reached a plateau. They concluded from these results that active transport takes up the labeled norepinephrine into a readily available pool from which it mixes more slowly with a second or reserve pool.
The storage compartment illustrated in figure 2 shows an active transport mechanism (heavy arrow) acting on a mobile norepinephrine pool which is in equilibrium with a reserve pool held in granules, presumably a complex of norepinephrine with intragranular components. Since norepinephrine is formed inside the storage compartment, the active transport system can be pictured as a pump (heavy arrow) which resists the outward passive diffusion of the amine (dotted arrow). It is important to keep in mind that despite the low diffusion coefficient of norepinephrine across a lipoidal membrane, its rate of simple diffusion will increase with the increase in the norepinephrine concentration in the mobile pool uiintil the foree of outward diffusion will finally counteract the inward force of active uptake. This combination of an active transport system and passive diffusion is commonly called a "pump and leak" system.
The model must explain how the norepinephrine content is maintained constant, without the amine overspilling onto receptors. On this point there has been disagreement; some believe that the content of norepinephrine is controlled by a feedback mechanism which stimulates its rate of synthesis as the stores are expended; others think that the catecholamine content is kept constant by continuous synthesis and wastage. The second view seemed more plausible to us, for it is a general rule in nature that stored substrates undergo continuous turnover, whether they are being utilized or not.
Recently 
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HOUR AFTER H3NE Figure 3 Time-course of H3NE content in heart afte-i.v. administration of labeled, amine to rats. nephrine biosynthesis.6 In the past the formation of a catecholamine has been measured from the rates of disappearance or formation of the labeled substance formed from a radioactive precursor. 8 It is not generally appreciated, however, that norepinephrine in sympathetic nerve endings can be labeled directly, by taking advantage of the active transport system which will take up H3NE from the blood stream into nerve endings. As first reported by Axelrod and his associates, H3NE is taken up by various tissues.9 They concluded that the labeled amine is absorbed by sympathetic nerve endings since it does not accumulate in tissues after sympathetic denervation.10 In our studies6 tracer amounts of highly labeled H3NE were injected intravenously into rats, guinea pigs, and mice. A few minutes later the H3NE level in heart was 50 or more times higher than that in blood, suggesting that the labeled amine was taken up by the same active transport system which maintains endogenous norepinephrine inside nerve endings. Our results in figure 3 , which describe the kinetics of the decline in radioactivity, indicate that H3NE is first taken up into a readily miscible pool from which it slowly diffuses into a seeond pool. The initial decline in the heart H3NE is relatively rapid but becomes exponential within 12 hours in the rat and guinea pig, and within 4 hours in the mouse. The exponential decline suggests that HI3NE has equilibrated throughout all the stored epinephrine and that the decline in radioactivity results from the continuous production of new unlabeled norepinephrine and the simultaneous removal of norepinephrine, labeled and unlabeled. Since the quantity of endogenous norepinephrine remains constant, the slope of the decline represents the combined turnover of both norepinephrine pools. For reasons described below, this turnover may be less than the actual rate of norepinephrine formation.
The diphasic decline in specific activity suggests that eiidogenous norepinephrine is stored in an open two-compartment system, as Circulation, Volume XXVIII, November 1963 shown in figure 4 . Immediately after the injection of HI3NE, the radioactivity is confined to the mobile pool 81 into which ilewly formed norepinephrine readily enters and from which the endogenous amine diffuses or is released by nerve impulses. Since most of the trafficking in the nerve ending goes on in this pool, it follows that during the time that it contains most of the H3NE, the decline in radioactivity will be most rapid. As the H3NE exchanges with S2, the reserve pool, the decline in radioactivity will become less abrupt and at equilibration will be exponential. Conventionally, Si may be regarded as the precursor and S2 the product-perhaps a complex of norepinephrine with ATP and other cellular components-and the specific activity of each pool will have the classical precursorproduct relationship: the specific activity of S2 starting from zero will progressively increase until it exceeds that of Si and declines in parallel. The ratio SA2/SA1 at equilibration will depend largely on the rate of norepinephrine exchange between the pools. If this rate is high, the specific activities will be almost equal and the rate of norepinephrine formation will not differ much from the turnover rate calculated from the exponential decline in H3NE. If the rate of exchange is slow, the specific activity of S2 will be higher than of Sl, and the actual rate of norepinephrine biosynthesis will be much greater than the turnover rate calculated from the decline of H3NE. In any case, a change in norepinephrine formation will be reflected by a corresponding change in the slope of the H3NE decline. Figure 3 is the sum of two exponentials, whose slopes can be readily calculated.6 From these values can be calculated the various fractional turnover rates, the relative pool sizes, Si and S2, the rate of norepinephrine synthesis and the ratio of specific activities, SA2/SA1, at equilibrium ( fig. 4) . The latter will indicate how much the actual rate of norepinephrine synthesis differs from that calculated from the decline in H3NE. Pre Since the formulation of the neurochemical transducer is schematic, a number of anatomic models could satisfy the kinetics of the twocompartment system of figure 4 . For example, the ntieimlbrane of each graniule in the nerve ending might possess a specialized transport system which maintains a mobile norepinephrine pool in equilibrium with a "chemically bound" pool. Recent studies by others'2' 13 have shown that granules from the adrenal medulla take up labeled epinephrine in the presence of adenosine triphosphate and Mg++ ions in vitro by a process which is blocked by reserpine and various metabolic inhibitors and has the kinetics characteristic of active transport. When the level of the label within the granules reaches a plateau, it is mixed with only a fraction of the endogenous norepinephrine, suggesting that the granules contain two pools of the amine.
The origin of the norepinephrine-containing granules is a puzzling problem since it is unlikely that they are formed in the nerve endings. It is possible that they are made in the cell bodies. Recent work, utilizing a new histologic technic for the fluorescent staining of norepinephrine in tissue slices, indicates the presence of significant amounts of the amine in the cell bodies of sympathetic ganglia.14 In addition, norepinephrine granules are found in the axons of postganglionic sympathetic nerves.'5 These results suggest that the granules are formed in the cell bodies and carried down to the nerve endings through channels in the endoplasmic reticulum.
With reference again to figure 2, the exponential decline of H3NE over a period of 72 hours suggests that the rate of norepinephrine formation is constant, irrespective of nerve stimulation. We have obtained experimental proof for this view 26 The effect of MAO inhibitors on blood pressure is another story and is discussed at the end of this paper.
The scheme in figure 6 also explains why reserpine given shortly after a MAO-blocking agent does not cause a rapid decline in braini norepinephrine. Although reserpine releases norepinephrine from the restraint of the "pump," the free amine is no longer inactivated by MAO. Sinee norepinephrine is literally trapped by the blood-brain barrier, the amine becomes available to reactive sites. The conclusion that MAO inhibitors counteract the reserpine-induced depletion of norepinephrine is contradicted by the pronouneed excitation observed in rabbits.16 5 short-lasting and do not appreciably lower stores of endogenous norepinephrine. We hope that more potent and longer-lasting inhibitors will soon be available. 6 . Reserpine and certain other Rauwolfia alkaloids impair the transport system which maintains monoamines in their mobile pools.16 As a result, the amines diffuse through the storage membranes and are metabolized by MAO (fig. 7) . Since the mobile and reserve pools are in a state of equilibrium, the intragranular amines will also reach MAO by way of the mobile pool. Although reserpine releases considerable amounts of norepinephrine, sympathetic activity is not markedly enhanced since the amine is released mainly onto MAO and the radioactivity from hearts previously labeled with H3NE appears in the blood almost entirely as acidic metabolites. 34 In contrast, after a train of nerve impulses the radioactivity appears mainly as the bases (norepinephrine and its methylated derivative). Similarly, Kopin et al. 35 have shown that reserpine increases the urinary excretion of radioactivity, much of which is in the form of the deaminated products.
The problem often arises whether reserpine affects two different mechanisms in releasing and blocking the uptake of norepinephrine. Different mechanisms for the uptake and release seem an unnecessary complication for if the pump part of a "pump and leak' process is inhibited, the loss of the catecholamines is explained by unopposed diffusion.
After reserpine inhibits norepinephrine storage, the amine is still formed at peripheral nerve endings but at such a slow rate that there is a deficiency of free norepinephrine at receptors. In contrast, norepinephrine in brain is formed relatively rapidly and after reserpine administration, the level of free amine at synapses is high enough to elicit a normal or even an increased sympathetic output from the central nervous system. 36 This drug acts like bretylium but is far more potent. 39 8. Guanethidine, a guanidine derivative, produces a variety of sympatholytic effects including the lowering of arterial pressure. The drug releases norepinephrine from pe--ripheral sympathetic neurons but not from the brain ( fig. 9 ), since the drug does not cross the blood-brain barrier in appreciable amounts. 40 We are entertaining the possibility that guanethidine acts oppositely to bretylium, and depletes peripheral stores of norepinephrine by persistent activation of the mechanism by which nerve impulses trigger the release of the amine.9 In accord with this view, pretreatment of rats with bretylium prevents guanethidine, but not reserpine, from lowering the heart norepinephrine level, a result which indicates that reserpine and guanethidine liberate the amines by different mechanisms (table 2) . In addition, guanethidine produces a sympathomimetic effect lasting 90 minutes in the spinal cat; neither bretylium nor BW 392C60 exerts this action ( fig. 10) . That guanethidine and reserpine deplete norepinephrine by different mechanisms is also shown by the different ways in which they release the-amine. Reserpine blocks the norepinephrine pump, thereby allowing the amine to diffuse onto MAO and form deaminated products. In contrast guanethidine releases the norepinephrine directly Circulation, Volume XXVIII, November 1963 onto the receptor sites; indeed recent studies from our laboratory show that guanethidine releases H3NE from the heart largely in the form of the bases, norepinephrine and normetanephrine. 4 Guanethidine might first release norepinephrine from the mobile pool after which the release of the amine would be limited by the rate at whieh the amine leaves the granular reserve pool. The pattern of release by guanethidine is in accord with this view. After the first hour the release of norepinephrine seems to follow a zero order reaction as though the rate-limiting step is the rate at which the reserve pool is liberated.
Preliminiary studies suggest that a-methylmetatyrosine and a-methyldopa might act similarly to guanethidine. For example, metaraminol (n-hydroxynorephedrine), a decarboxylation product of a-mnethyl-metatyrosine (a-MMT) is an extraordinarily potent depleter of peripheral norepinephrine. 43 Our studies show that after nietaraminol is given, the radioactivity from the heart labeled with H3NE appears almost entirely as bases (norepinephrine and normetaliephrine), suggesting that metaraminol, like guanethidine, releases norepinephrinie onito receptor sites.34 Since a-inethyl-metatyrosinie and a-methyldopa lower the norepinephrine levels through the action of their products of decarboxylation, it muay be presumed that these amino acids also release nlorepinephrine directly onto receptors.
Since amuphetaminie also appears to release norepinephrine onto receptors, it is therefore of considerable initerest that small doses of amphetamine, metamphetamine, and ephedrine not only prevent guanethidine from depleting norepinephrine but counteract the pharmacologic effects of auaiiethidine. 44 5 Hypotensive Effects of MAO Inhibitors Clinically used M1AO inihibitors generally lower blood pressure. Our concept of the n-eurochemical transducer has helped us in studies of the mechanism of this action. After Dr. Gessa demonstrated that the potent bretylium-like compound, BW 392C60, is a Table 3 shows that a number of these drugs prevent the decline in heart norepinephrine produced by guanethidine, some of them being more active than bretylium. Since bretylium and BW 392C60 also prevent the nierve impulse-induced release of norepinephrine, the possibility was entertained that these compounds and MAO inhibitors might lower blood pressure by similar mechaniisms.
Experimenits were first carried out to learn wlhether the antiguanethidine action of MAO inhibitors depends on blockade of MAO. 47 The two actions were shown to be independen-t (table 4) . For example, BW 392C60 prevents guanethidine from releasing norepinephrine in doses having only a small effect on MAO in vivo. In additioni, bretylium blocks guanethidinie action in doses having no effect omi MAO. A clear-cut separation between the two actionis is shown with iproniazid, which antagfonizes the action of guanethidine in doses producing little inhibition of MAO. Although the separation of the two actions is not so definite with pargyline, this drug also completely antagonizes the action of guanethidine in doses that only partially bloek Circulation, Voltume XXVIII, November 196,?
MAO. With phenelzine and tranylcypromine, however, the two actions could not be separated.
We deternmined the effect of the drugs on the reactivity of the peripheral adrenergic nervous system to electrical stimulation of the celiac ganglion ( fig. 11) . Bretylium blocks the increase in blood pressure elicited by low frequency stimulation thouth. not that elicited by high frequency stimulation; whereas the more potent drug BW 392C60 blocks the response even at high frequeney stimulation. Figure 12 Blood pressure responses to admiizistration of DMPP. Adrenalectomized cats wtere anesthetized with chloralose and drugs were injected as indicated in figure, except for pargyline, which was injected as described in figure 1 reactive sites; the more rapid the turnover of norepinephrine the more free norepinephrine will be available to overcome the bretylium-like effect. It would be of great interest to compare the rates of norepinephrine biosynthesis in the nictitating membrane and in the blood vessels.
Circulation, Volume XXVIII, November 1963 It is pertinent that the bretylium-like action elicited by MAO In the absence of sympathetic tone, norepinephrine can leave the storage compartments bv simple diffusion through the lipoid membrane onto MAO. After nerve stimulation the amine is released directly onto the receptor sites and reaches the blood stream in the form of bases.
This model for the transducer helps to explain the action of a number of drugs. Amphetamine increases blood pressure by releasing a small amount of norepinephrine at peripheral sympathetic nerve endings. Reserpine lowers blood pressure by inhibiting the norepinephrine pump which maintains the amine in the mobile pool; as a result the peripheral stores of amine are depleted by an uncompensated diffusion of the amine onto MAO.
Bretylium and a number of benzyl derivatives of guanidine lower blood pressure by preventing nerve impulses from releasing norepinephrine at sympathetic nerve endings. Guanethidine and a number of phenylethyl guanidine derivatives cause lowering of arterial pressure by depleting the peripheral stores of norepinephrine perhaps through a persistent activation of the physiologic release mechanism. Alpha-methyldopa, a-methylmetatyrosine, and metaraminol may act in a similar way.
Finally, considerable evidence suggests that MAO inhibitors lower blood pressure bv exerting a bretylium-like action. They not only prevent guanethidine from releasing norepinephrine but like bretylium they appear to prevent nerve impulses from releasing norepinephrine onto receptors.
